Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the second quarter ended December 31, 2015. The report is an Appendix 4C Quarterly Report for entities admitted on the basis of commitments, filed on January 29, 2016.
Key Financial Metrics
Revenue: The filing reports $0 in receipts from customers for both the current quarter and the year-to-date period.
Cash Flow:
- Net Operating Cash Flows: $(2,799) thousand for the quarter; $(7,371) thousand year-to-date.
- Net Investing Cash Flows: $(2) thousand for the quarter; $(2) thousand year-to-date.
- Net Financing Cash Flows: $0 for the quarter and year-to-date.
- Net Decrease in Cash: $(2,801) thousand for the quarter; $(7,373) thousand year-to-date.
Liquidity and Cash Position:
- Cash at Beginning of Quarter: $32,988 thousand.
- Cash at End of Quarter: $29,059 thousand.
- Cash Composition: $26,059 thousand on hand/at bank and $3,000 thousand in deposits at call.
Debt and Financing Facilities: The company reported no loan facilities or credit standby arrangements available or used.
Profit and Margins: The filing text does not provide a clear value for net profit, loss, or profit margins, as it focuses exclusively on cash flow activities.
Material Changes
The primary material change is the continued burn of cash without operating revenue. Operating cash outflows for the quarter totaled approximately $2.8 million, driven primarily by research and development costs ($1,770 thousand) and staff costs ($636 thousand). There were no acquisitions, disposals, or new borrowings during the period.
Guidance, Outlook, and Risks
The filing text does not provide specific forward-looking guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the standard compliance statements. The company remains in a pre-revenue stage with no financing activities recorded in the quarter.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name ("Altery Therapeutics Ltd") and the filing registrant name ("Prana Biotechnology Limited").
- Confirm the sustainability of the current cash burn rate of approximately $2.8 million per quarter against the remaining cash balance of $29.1 million.
- Review the specific milestones for the $1.77 million in R&D spending to assess progress toward revenue generation.
- Check for any unrecorded financing arrangements or off-balance-sheet liabilities not captured in the "Financing Facilities Available" section.